. home.aspx

NEWS

home.aspx
   


Antibe engages global CMO to support planned pain drug partnership Like

December 16, 2019 / Nick Taylor
SHARESHARESHARE

Toronto, Canada-based Antibe Therapeutics is running a Phase IIb clinical trial of ATB-346, a hydrogen sulfide-releasing derivative of naproxen, to generate more efficacy and metabolism data. Antibe designed ATB-346 to deliver the positive effects on pain and inflammation that make naproxen a widely used joint disease therapy, without also causing ulcers and other gastrointestinal problems associated with the nonsteroidal anti-inflammatory drug (NSAID). The anticipated Phase IIb results are intended for two audiences, namely regulators and potential partners. Antibe had the same audiences in mind when it made a recent decision to engage a leading global contract manufacturing organization. Antibe has long planned to develop ATB-346 up to the end of Phase II, describing the completion of mid-phase development as a possible strategic exit point